Medy-Tox Inc. (KOSDAQ: 086900)
South Korea flag South Korea · Delayed Price · Currency is KRW
126,200
+300 (0.24%)
Nov 15, 2024, 9:00 AM KST

Medy-Tox Company Description

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea.

It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles.

The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials.

In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method.

It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally.

Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.

Medy-Tox Inc.
Country South Korea
Founded 2000
Industry Biological Products, Except Diagnostic Substances
Employees 703
CEO Hyun-Ho Jung

Contact Details

Address:
78, Gak-ri 1-gil
Cheongju
South Korea
Phone 82 4 3217 1555
Website medy-tox.co.kr

Stock Details

Ticker Symbol 086900
Exchange KOSDAQ
Fiscal Year January - December
Reporting Currency KRW
SIC Code 2836

Key Executives

Name Position
Hyun-Ho Jung Chief Executive Officer